Información adicional

• Num_publicacion 76(9-10)
• Resumen_ingles
  Introduction: Omalizumab is a monoclonal antibody against immunoglobulin E used in the treatment of severe allergic asthma. The aim of this study was to describe, in pediatric patients, the effects of omalizumab in pulmonary function values and in the nitric oxide concentration levels in exhaled breath (FeNO).
  Material and methods: We performed a statistical analysis of lung function and FeNO evolution in 13 children treated with omalizumab in a pediatric service, between year 2010 and 2016.
  Results: A statistically significant improvement was observed after 3 months of treatment, which remained stable over time, in lung function values (pre-treatment: forced vital capacity [FVC] 84.1% and forced expiratory volume in the first second [FEV₁] 72%; after treatment: FVC 101% [p= 0.02] and FEV₁ 92% [p= 0.01]). A significant improvement was also detected in the FeNO levels (pre-treatment: 82 ppb; after treatment: 36 ppb).
  Conclusions: In our pediatric patients with severe asthma, omalizumab was able to improve and maintain stable in time both pulmonary function and FeNO values.
   
• Palabras_clave_ingles Severe asthma Children Pulmonary function Nitric oxide concentration levels in exhaled breath Omalizumab
• Todos_autores L. Moreno-Galarraga^1,2, L. Urriza Yeregui¹, I. Urriza Ripa¹, A. Fernández-Montero^2,3, D. Peñafiel Freire¹, N. Viguria Sánchez^1,2
• autores listados L. Moreno-Galarraga, L. Urriza Yeregui, I. Urriza Ripa, A. Fernández-Montero, D. Peñafiel Freire, N. Viguria Sánchez
• Correspondecia
  L. Moreno-Galarraga. Servicio de Pediatría. Neumología Infantil. Complejo Hospitalario de Navarra. Irunlarrea, 3. 31008 Pamplona (Navarra).
  Correo electrónico: laura.moreno.galarraga@cfnavarra.es
• Titulo_ingles Lung function evolution in children with severe asthma treated with omalizumab
• Centros_trabajo ¹Servicio de Pediatría. Complejo Hospitalario de Navarra. Pamplona (Navarra). ²IdisNa: Instituto de Investigación Sanitaria de Navarra. ³Departamento de Medicina Preventiva y Salud Pública. Universidad de Navarra. Pamplona (Navarra)
• Publicado en Acta Pediatr Esp. 2018; 76(9-10): 105-108
• copyright ©2018 Ediciones Mayo, S.A.
• Fecha recepcion 23/04/17
• Fecha aceptacion 14/06/17
• Tipo de Artículo Clínico (Microdatos) Observational Study